Abstract Number: 1797 • 2013 ACR/ARHP Annual Meeting
A Randomized, Dose-Ranging, Placebo-Controlled, 84-Day Study Of INCB039110, a Selective Janus Kinase-1 Inhibitor, In Patients With Active Rheumatoid Arthritis
Background/Purpose: To characterize the safety and efficacy of INCB039110, a novel and selective JAK1 inhibitor, in patients with active RA. Methods: This phase 2, multicenter…Abstract Number: 1772 • 2013 ACR/ARHP Annual Meeting
Better Cost-Effectiveness and Worker Productivity In Triple DMARD Therapy Versus Methotrexate Monotherapy In Early Rheumatoid Arthritis; Cost-Utility Analysis Of The Treach Trial
Background/Purpose: In the treatment in the Rotterdam Early Arthritis Cohort (tREACH) trial we showed that treatment goals were attained faster and maintained with less treatment…Abstract Number: 1482 • 2013 ACR/ARHP Annual Meeting
Survival Of Biological Treatment In Chronic Inflammatory Arthritis: A Preliminary Analysis Of 13 Years Of Follow Up In Clinical Practice
Background/Purpose: The wide use of biological therapies (BTs) has largely modified the therapeutic approach in Chronic Inflammatory Arthritis (CIA). These relatively new drugs have different…Abstract Number: 1484 • 2013 ACR/ARHP Annual Meeting
Treatment With The Glucagon-Like Peptide-1 Analogue Liraglutide Is Associated With Amelioration Of Disease Activity In a Prospective Cohort Study Of Patients With Inflammatory Arthritis
Background/Purpose: Glucagon-like peptide-1 (GLP-1) analogues such as liraglutide, which are used for the treatment of type 2 diabetes (T2DM), mimic the action of endogenous incretin…Abstract Number: 1460 • 2013 ACR/ARHP Annual Meeting
10 Years Of Treat-To-Target Therapy In Rheumatoid Arthritis Patients (the BeSt study): Clinical and Radiological Outcomes
Background/Purpose: Long term studies with treat-to-target therapy are essential to guide treatment strategies. We report on a study that compared clinical and radiological outcomes of…Abstract Number: 1475 • 2013 ACR/ARHP Annual Meeting
Subcutaneous Delivery Of Methotrexate Is Associated With Improved Treatment Survival Compared To Oral Administration For The Initial Treatment Of Patients With Early Rheumatoid Arthritis
Background/Purpose: To determine the comparative survival of initial treatment with subcutaneous (sc) methotrexate (MTX) versus oral MTX for patients with early rheumatoid arthritis (ERA) in…Abstract Number: 1446 • 2013 ACR/ARHP Annual Meeting
The Efficacy Of Etanercept In Combination With Methotrexate In Moderate To Severe Rheumatoid Arthritis Is Not Dependent On The Dosage Of Methotrexate
Background/Purpose: Anti-TNF therapy in combination with a synthetic DMARD such as methotrexate (MTX) has been extensively shown to be superior to MTX and anti-TNF therapy…Abstract Number: 1456 • 2013 ACR/ARHP Annual Meeting
Golimumab Levels, Anti-Drug Antibodies and Clinical Response In Rheumatoid Arthritis Patients At 28 Week Of Follow-Up
Background/Purpose: Low drug levels of anti-Tumor Necrosis Factor (TNF) therapies are related to poorer response in patients with rheumatoid arthritis (RA). Furthermore, anti-drug antibodies (ADA)…Abstract Number: 1285 • 2013 ACR/ARHP Annual Meeting
Choline Kinase: A Novel Target For Rheumatoid Arthritis
Background/Purpose: Choline kinase (ChoKa) is an essential enzyme for phosphatidylcholine biosynthesis and is required for cell proliferation. The enzyme has also been implicated in cancer…Abstract Number: 1057 • 2013 ACR/ARHP Annual Meeting
Regional Variations In Rheumatoid Arthritis Treatment and Health Outcomes Across The United States
Background/Purpose: Current ACR guidelines call for treatment of rheumatoid arthritis (RA) with non-biologic or biologic disease modifying anti-rheumatic drugs (DMARDs). The National Quality Forum has…Abstract Number: 800 • 2013 ACR/ARHP Annual Meeting
A Strategy For Selecting Individuals With RA For Reduction Of Anti-TNF Therapy Using Combined Clinical and Ultrasound Assessment
Background/Purpose: Reducing the dose of biological therapy may be possible for patients with rheumatoid arthritis (RA) who have achieved remission or low disease activity (LDA). …Abstract Number: 497 • 2012 ACR/ARHP Annual Meeting
Golimumab Drug Utilization Patterns in Canada – Higher Retention Rate in Golimumab Treated Rheumatoid Arthritis Patients Compared to Etanercept and Adalimumab
Background/Purpose: Golimumab is a monthly self-injected anti-tumor necrosis factor alpha therapy for patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), and psoriatic arthritis (PsA). It…Abstract Number: 499 • 2012 ACR/ARHP Annual Meeting
What Is the Right Dose to Start Methotrexate (7.5 or 15mg) in Rheumatoid Arthritis? (A Randomized Controlled Trial)
Background/Purpose: Recent recommendations have suggested higher starting doses of methotrexate, i.e. 15 mg/week (3E initiative) in rheumatoid arthritis. However, studies comparing conventional (7.5mg) and newer…Abstract Number: 372 • 2012 ACR/ARHP Annual Meeting
TRAF1/C5 Locus Is Associated with Response to Anti-Tumor Necrosis Factor Therapy in Patients with Rheumatoid Arthritis
Background/Purpose: Some of the allelic variants associated with rheumatoid arthritis (RA) susceptibility are related to tumor necrosis factor (TNF) signaling pathways. We hypothesized that they…Abstract Number: 2638 • 2012 ACR/ARHP Annual Meeting
Biologic Switching Among Patients with Rheumatoid Arthritis in the United States, 2004-2011
Background/Purpose: While studies have assessed the efficacy of switching among biologic disease-modifying antirheumatic drugs (bDMARD), there is a lack of knowledge regarding the patterns of…
- « Previous Page
- 1
- …
- 7
- 8
- 9
- 10
- Next Page »